Loading
companiesCompany
Jazz Pharmaceuticals
Jazz Pharmaceuticals, based in Dublin, sells zanidatamab (Ziihera), a HER2-targeting antibody, outside Asia for biliary tract and gastro-oesophageal cancer, alongside Rylaze, Zepzelca (lurbinectedin) and CPX-351 for acute myeloid leukaemia. Whether zanidatamab can grow from a rare bile duct indication into gastric cancer is its open question.
Overview
Jazz Pharmaceuticals, based in Dublin and listed as JAZZ, commercialises zanidatamab, sold as Ziihera, outside Asia, in biliary tract and gastro-oesophageal cancer. Its oncology portfolio also includes Rylaze asparaginase and Zepzelca, or lurbinectedin, partnered with PharmaMar, along with CPX-351 for acute myeloid leukaemia, defibrotide and dordaviprone. OnCo links it to biliary tract, gallbladder and gastric cancer, acute myeloid leukaemia and Ewing sarcoma, and to Zai Lab as a partner. Whether zanidatamab can expand from a rare HER2-positive bile duct indication into gastric cancer at scale is the open question. Zanidatamab has its own page.
Headquarters
Dublin, IE
Scorecard
All companies#23of 1244 companies, score 98
- approved products +42
- targets +2
- modalities +8
- regions +6
- 24-month regulatory events +10
- registry trials +30
7 approved, 0 in phase 3, 0 earlier, 1 targets, 407 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2022-10-19 | Zymeworks to Jazz Pharmaceuticals Zanidatamab, HER2 biparatopic bispecific antibody | Licence | $50m | up to $1.76bn | source |
Type
Biotech · JAZZ
Stage
Public
Website
ApprovedBiparatopic bispecific antibody (HER2)
Zanidatamab · Ziihera
Zanidatamab (Ziihera) is an antibody that grabs HER2 at two different spots, approved for HER2+ bile duct cancer.
ApprovedEnzyme therapy (recombinant asparaginase)
Enrylaze is a replacement asparaginase for children and adults with acute lymphoblastic leukaemia or lymphoblastic lymphoma whose bodies have reacted against, or quietly neutralised, the usual E. coli asparaginase. It keeps the asparagine-starving part of their chemotherapy going.
ApprovedEnzyme therapy
Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase) · Oncaspar / Asparlas / Rylaze / Erwinaze
An enzyme that starves leukaemia cells of an amino acid they cannot make; a mainstay of childhood ALL therapy for 50 years, with new versions solving allergy and supply problems.
ApprovedLiposomal cytotoxic formulation
The two old chemotherapy drugs packed together into tiny fat bubbles at a fixed ratio, which doubled five-year survival in older adults with high-risk AML.
ApprovedPolydisperse oligonucleotide mixture (endothelial protectant)
Defibrotide · Defitelio
Defibrotide (Defitelio) is the only approved treatment for hepatic veno-occlusive disease, a life-threatening liver complication of high-dose chemotherapy before stem cell transplant, in patients whose kidneys or lungs are also failing.
ApprovedSmall-molecule imipridone (ClpP agonist / DRD2 antagonist)
Dordaviprone · Modeyso
Dordaviprone is the first drug ever approved for a childhood and young-adult brain tumour that had none, diffuse midline glioma with the H3 K27M mutation (August 2025).
ApprovedCytotoxic (transcription inhibitor)
Lurbinectedin · Zepzelca
A marine-derived chemotherapy that jams cancer's gene-reading machinery, approved for relapsed small-cell lung cancer and, since 2025, as first-line maintenance with atezolizumab.
observationalThe Lancet Oncology 2023217 citations
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
One cancer page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observationalBlood 2016changed practice233 citations
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
This is the trial behind defibrotide's March 2016 US approval, the only approved treatment for hepatic veno-occlusive disease with organ failure after transplant. The historical-control design was accepted because a randomised trial in a condition this lethal and rare was judged unfeasible; the gain is meaningful but most patients still died.
Similar pages
- CompanyZymeworks
Shares Zai Lab, HERIZON-BTC-302, Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study, HERIZON-BTC-01.
- IdeaReflex HER2 testing of every advanced gallbladder and extrahepatic biliary cancer
Shares HERIZON-BTC-302, Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study, HERIZON-BTC-01, Zanidatamab.
- CompanyPharmaMar
Shares IMforte, ATLANTIS, Lurbinectedin, Ewing sarcoma.
- TrialLurbinectedin basket trial, small-cell lung cancer cohort
Shares IMforte, ATLANTIS, Lurbinectedin, Extensive-stage small-cell lung cancer.
- TrialA Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Shares Crisantaspase (recombinant Erwinia asparaginase), CPX-351 (liposomal daunorubicin-cytarabine), Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase), Acute myeloid leukaemia.
- PairingChemo-immunotherapy induction → maintenance intensification (SCLC)
Shares IMforte, Lurbinectedin, Extensive-stage small-cell lung cancer, Small-cell lung cancer.
- Key paperHER2 status in extrahepatic cholangiocarcinoma and gallbladder carcinoma: concordance between immunohistochemistry and chromogenic in situ hybridization in 140 cases
Shares HERIZON-BTC-01, Zanidatamab, Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials, Biliary tract cancer (cholangiocarcinoma).
- PersonPaul G. Richardson
Shares Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure, Study 2005-01.
cancers
fronts
drugs
ApprovedEnzyme therapy
Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase) · Oncaspar / Asparlas / Rylaze / Erwinaze
ApprovedLiposomal cytotoxic formulation
ApprovedEnzyme therapy (recombinant asparaginase)
ApprovedPolydisperse oligonucleotide mixture (endothelial protectant)
Defibrotide · Defitelio
ApprovedSmall-molecule imipridone (ClpP agonist / DRD2 antagonist)
Dordaviprone · Modeyso
ApprovedCytotoxic (transcription inhibitor)
Lurbinectedin · Zepzelca
ApprovedBiparatopic bispecific antibody (HER2)
Zanidatamab · Ziihera
companies
trials
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerA Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsA Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment oA Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCACTIONATLANTISClinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.CPX-351 Study 301HERIZON-BTC-01HERIZON-BTC-302HERIZON-GEA-01IMforteLurbinectedin With Osimertinib in Transformed Small Cell Lung CancerPRE-ISPY Phase I/II Oncology Platform ProgramStudy 2005-01Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing SarcomaStudy of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma